STING1 and glioblastoma: Increased expression of STING following decitabine treatment could also be therapeutically relevant, potentially increasing sensitivity to radiation and cell therapies.53,54 STING activation has been shown to promote NK cell-mediated antitumor responses in glioblastoma models, such that use of a STING agonist led to upregulation of NK cell and T-cell infiltration and subsequent tumor cell killing, while in vivo depletion of the NK cell population abolished the efficacy of the STING agonist.